Creative Medical Technology
CELZ
9 hedge funds and large institutions have $96.2K invested in Creative Medical Technology in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, reducing their positions, and 8 closing their positions.
1.23% more ownership
Funds ownership: 0.25% → 1.47% (+1.2%)
40% less funds holding
Funds holding: 15 → 9 (-6)
45% less capital invested
Capital invested by funds: $176K → $96.2K (-$79.7K)
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$66.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.55K |
| 3 |
IA
IFP Advisors
Tampa,
Florida
|
+$290 |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$116 |
| 5 |
ODG
O'Dell Group
Cincinnati,
Ohio
|
+$6 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$62.1K |
| 2 |
VF
Virtu Financial
New York
|
-$26K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$13.8K |
| 4 |
State Street
Boston,
Massachusetts
|
-$12.7K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$10.7K |
CELZ Hedge Fund Activity: Q2 2023 in Review
9 of the 6,382 institutional investors tracked by Wall St. Rank reported a position in Creative Medical Technology (CELZ) for Q2 2023, worth a combined $96.2K — down 45% from $176K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CELZ and 2 opened new positions — a net loss of 6 holders — while 0 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $66.9K. The largest seller was Geode Capital Management, exiting entirely with an estimated $62.1K sold.
- 9 institutional investors held Creative Medical Technology (CELZ) as of Q2 2023, down from 15 in Q1 2023.
- Funds reported $96.2K of Creative Medical Technology stock for Q2 2023, down 45% quarter-over-quarter.
- 2 funds opened new Creative Medical Technology positions in Q2 2023 and 8 closed out, a net change of -6 holders.
- The largest Creative Medical Technology buyer in Q2 2023 was Vanguard Group, an estimated $66.9K added.
- The largest Creative Medical Technology seller in Q2 2023 was Geode Capital Management, an estimated $62.1K sold.
Based on aggregated 13F filings for Q2 2023.